Epigenetic regulation of microRNA expression in renal cell carcinoma

Biochem Biophys Res Commun. 2013 Jun 21;436(1):79-84. doi: 10.1016/j.bbrc.2013.05.061. Epub 2013 May 22.

Abstract

The underlying mechanisms of microRNA deregulation in cancer cells include epigenetic modifications, which play a crucial role in carcinogenesis. We demonstrate that numerous microRNAs are induced in renal cell carcinoma cell lines after treatment with inhibitors of the DNA-methyltransferase (5-aza-2'-deoxycytidine) and the histone-deacetylase (suberoylanilide hydroxamic acid). We provide evidence that enrichment of H3 and H3K18 acetylation at the miR-9 promoter is causative for re-expression, while DNA hypermethylation remains unchanged. Our experiments show that the treatment with the epigenetic drugs causes re-expression of silenced microRNAs with putative tumor suppressive function in ccRCC cell lines.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Azacitidine / analogs & derivatives
  • Azacitidine / pharmacology
  • Carcinoma, Renal Cell / genetics
  • Carcinoma, Renal Cell / metabolism*
  • Cell Line, Tumor
  • Cell Proliferation
  • Cell Survival
  • DNA Methylation
  • DNA Modification Methylases / metabolism
  • Decitabine
  • Epigenesis, Genetic*
  • Gene Expression Regulation, Neoplastic
  • Gene Silencing
  • Histone Deacetylases / metabolism
  • Histones / metabolism
  • Humans
  • Hydroxamic Acids / pharmacology
  • Kidney Neoplasms / genetics
  • Kidney Neoplasms / metabolism*
  • MicroRNAs / metabolism*
  • Promoter Regions, Genetic
  • RNA / metabolism
  • Vorinostat

Substances

  • Histones
  • Hydroxamic Acids
  • MicroRNAs
  • Vorinostat
  • RNA
  • Decitabine
  • DNA Modification Methylases
  • Histone Deacetylases
  • Azacitidine